Moderna (NASDAQ:MRNA) Trading Down 6.3% - What's Next?

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares fell 6.3% during mid-day trading on Tuesday . The stock traded as low as $34.08 and last traded at $33.69. 1,468,336 shares traded hands during trading, a decline of 88% from the average session volume of 12,428,438 shares. The stock had previously closed at $35.96.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MRNA. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday, January 15th. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and dropped their price target for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Argus downgraded shares of Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating on the stock in a report on Tuesday, February 11th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $59.60.

Remove Ads

Moderna Stock Up 0.9 %

The business has a fifty day simple moving average of $35.94 and a two-hundred day simple moving average of $47.37. The company has a market capitalization of $13.36 billion, a price-to-earnings ratio of -3.73 and a beta of 1.86.

Institutional Trading of Moderna

Large investors have recently bought and sold shares of the stock. Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Moderna in the 4th quarter worth about $4,486,000. PKO Investment Management Joint Stock Co bought a new stake in Moderna during the fourth quarter worth about $249,000. Probity Advisors Inc. increased its holdings in shares of Moderna by 121.8% during the fourth quarter. Probity Advisors Inc. now owns 10,746 shares of the company's stock worth $447,000 after buying an additional 5,902 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Moderna in the fourth quarter valued at approximately $18,084,000. Finally, B. Riley Wealth Advisors Inc. boosted its holdings in shares of Moderna by 17.8% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 6,158 shares of the company's stock worth $256,000 after acquiring an additional 929 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.